Clinical TrialMay 22, 2026, 08:02 AM
Ascentage Pharma Presents Positive Clinical Data at ASCO 2026
AI Summary
Ascentage Pharma announced the release of latest clinical data from multiple trials at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Six abstracts were selected for presentation, including three rapid oral presentations, showcasing data from lead drug candidates olverembatinib, lisaftoclax, and alrizomadlin with positive efficacy and safety profiles. Additionally, the company's Annual General Meeting (AGM) on May 20, 2026, saw all proposed resolutions passed, including the re-election of directors, re-appointment of auditors, and approval of general mandates for share allotment and repurchase.
Key Highlights
- Ascentage Pharma presented 6 clinical abstracts at ASCO 2026, including 3 rapid oral presentations.
- Olverembatinib combined with blinatumomab achieved complete response in 4 of 5 MRD-positive CML-LBP/Ph+ BCP-ALL patients.
- Olverembatinib as second-line CP-CML therapy showed 91.3% complete cytogenetic response and 60.9% major molecular response at cycle 24.
- Alrizomadlin monotherapy achieved 1 complete response in pediatric rhabdomyosarcoma; combination with lisaftoclax had 30% objective response rate.
- Olverembatinib in SDH-deficient GIST showed 23.1% partial response and median progression-free survival of 25.7 months.
- Phase 3 POLARIS-2 trial for olverembatinib in CP-CML and GLORA trial for lisaftoclax in CLL/SLL are actively enrolling patients.
- Shareholders approved general mandates for allotting up to 20% new shares and repurchasing up to 10% of shares.
- Shareholders approved proposed grants of RSUs and Options to Dr. Yang and Dr. Zhai.
Price Impact
More from AAPG